Filter by Topic
Filter by Format
Zhang Lizhu is a Chinese gynecologist and researcher. For most of her career, she worked in the Peking Medical College Third Hospital, renamed in 2000, Peking University Third Hospital. There, she led a team of researchers and physicians in the study of human in vitro fertilization (IVF) and embryo transfer (ET) technology. Zhang and her colleagues contributed to the birth of the first test-tube baby in Mainland China in 1988.
By 2011, researchers in the US had established that non-invasive blood tests can accurately determine the gender of a human fetus as early as seven weeks after fertilization. Experts predicted that this ability may encourage the use of prenatal sex screening tests by women interested to know the gender of their fetuses. As more people begin to use non-invasive blood tests that accurately determine the sex of the fetus at 7 weeks, many ethical questions pertaining to regulation, the consequences of gender-imbalanced societies, and altered meanings of the parent-child relationship.
Estrogen is the primary sex hormone in women and it functions during the reproductive menstrual cycle. Women have three major types of estrogen: estrone, estradiol, and estriol, which bind to and activate receptors within the body. Researchers discovered the three types of estrogen over a period of seven years, contributing to more detailed descriptions of the menstrual cycle. Each type of estrogen molecule contains a slightly different arrangement or number of atoms that in turn causes some of the estrogens to be more active than others.
China's First Baby Conceived through In Vitro Fertilization-Embryonic Transfer, by Zhang Lizhu's Research Team
On 10 March 1988, China's first baby conceived through human in vitro fertilization (IVF) and embryo transfer (ET), commonly referred to as a test-tube baby, was born at the Peking Hospital (PUTH) in Beijing. This birth was reported in numerous media reports as a huge step forward in China's long march to keep pace with global advances in science and technology. Led by gynecologist Zhang Lizhu, the PUTH research team had devoted more than four years to the human IVF-ET project.
Thalidomide, a drug capable of causing fetal abnormalities (teratogen), has caused greater than ten thousand birth defects worldwide since its introduction to the market as a pharmaceutical agent. Prior to discovering thalidomide's teratogenic effects in the early 1960s, the US Food and Drug Administration (FDA) did not place regulations on drug approval or monitoring as it later did. By 1962, approximately 20,000 patients in the US had taken thalidomide as part of an unregulated clinical trial before any actions were taken to stop thalidomide's distribution.